IL304232A - Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome - Google Patents

Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Info

Publication number
IL304232A
IL304232A IL304232A IL30423223A IL304232A IL 304232 A IL304232 A IL 304232A IL 304232 A IL304232 A IL 304232A IL 30423223 A IL30423223 A IL 30423223A IL 304232 A IL304232 A IL 304232A
Authority
IL
Israel
Prior art keywords
tesquinimod
salt
treatment
pharmaceutically acceptable
myelodysplastic syndrome
Prior art date
Application number
IL304232A
Other languages
English (en)
Hebrew (he)
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of IL304232A publication Critical patent/IL304232A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL304232A 2021-01-18 2023-07-04 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome IL304232A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21152018 2021-01-18
EP21201509 2021-10-07
EP21205665 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
IL304232A true IL304232A (en) 2023-09-01

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304232A IL304232A (en) 2021-01-18 2023-07-04 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US20240091215A1 (https=)
EP (1) EP4277628B1 (https=)
JP (1) JP7837338B2 (https=)
KR (1) KR20230133317A (https=)
AU (1) AU2022208424A1 (https=)
CA (1) CA3204120A1 (https=)
ES (1) ES3057099T3 (https=)
IL (1) IL304232A (https=)
MX (1) MX2023008016A (https=)
PL (1) PL4277628T3 (https=)
WO (1) WO2022152902A1 (https=)
ZA (1) ZA202307855B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP3711484A1 (en) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
KR20160136323A (ko) * 2014-02-28 2016-11-29 인사이트 코포레이션 골수형성이상증후군 치료용 jak1 억제제
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) * 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
JP2019127473A (ja) * 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
CA3204120A1 (en) 2022-07-21
EP4277628C0 (en) 2025-09-24
WO2022152902A1 (en) 2022-07-21
EP4277628A1 (en) 2023-11-22
AU2022208424A1 (en) 2023-08-24
JP7837338B2 (ja) 2026-03-30
KR20230133317A (ko) 2023-09-19
ZA202307855B (en) 2025-12-17
PL4277628T3 (pl) 2026-02-09
JP2024503372A (ja) 2024-01-25
ES3057099T3 (en) 2026-02-26
EP4277628B1 (en) 2025-09-24
AU2022208424A9 (en) 2024-05-09
US20240091215A1 (en) 2024-03-21
MX2023008016A (es) 2023-07-13

Similar Documents

Publication Publication Date Title
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
IL304232A (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
MX2024010140A (es) Nuevos metodos.
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
PL3426250T3 (pl) Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
HUE058931T2 (hu) Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
SI4076652T1 (sl) Farmacevtsko sprejemljiva sol atrazentana za uporabo v zdravljenju iga nefropatije
IL304312A (en) Pharmaceutically acceptable salts of psilocin and uses thereof
EP3914203A4 (en) METHODS OF TREATMENT OF OBSTRUCTIVE SLEEP APNEA
IL304305A (en) Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
KR20240101580A9 (ko) Hbv 치료를 위한 약학 조합물
EP3814326A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
EP4198021A4 (en) DONEPEZIL ETHER PALMITATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
HRP20251695T1 (hr) Terapijski agensi za uporabu u liječenju sindroma nemirnih nogu
IL312885A (en) Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
PL3801460T3 (pl) Sole amlodypiny do stosowania miejscowego w leczeniu chorób odbytu i odbytnicy
PL4182311T3 (pl) Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych
IL286818A (en) Mirikizumab for use in a method of treating crohns disease
PL4072532T3 (pl) Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
EP4269468A4 (en) SURFACE TREATMENT AGENT
EP4242249A4 (en) SURFACE TREATMENT AGENT
IL280639A (en) History of thiazoles and their pharmaceutically acceptable salts